

Membrane-dependent relief of translation elongation arrest on pseudouridine- and N¹-methyl-pseudouridine-modified mRNAs

Yuri V. Svitkin,^{1,2,*} Anne-Claude Gingras,³ and Nahum Sonenberg^{1,2,*}

¹Department of Biochemistry, McGill University, Montréal, Québec, H3A 1A3, Canada

²Rosalind and Morris Goodman Cancer Institute, Montréal, Québec, H3A 1A3, Canada

³Lunenfeld-Tanenbaum Research Institute, Sinai Health System, and Department of Molecular Genetics, University of Toronto, Toronto, Ontario, M5G 1X5, Canada

* To whom correspondence should be addressed.

Tel: +1 514 398 7274; Fax: +1 514 398 1286; Email: nahum.sonenberg@mcgill.ca or

Tel: +1 514 398 5695; Fax: +1 514 398 1286; Email: yuri.svitkine@mcgill.ca.

SUPPLEMENTARY DATA

Contents:

Supplementary Figures S1-S5




Figure S1. Ψ and N1m Ψ nucleoside modifications in Luc mRNA enhance translation in MN-untreated RRL. Unmodified Luc, Ψ -Luc, and N1m Ψ -Luc mRNA (4 μ g/ml) were translated at 30°C for 1 h. One μ l aliquots of the reaction mixtures were assayed for luciferase activity. The mean values of the triplicate data \pm SD are shown.




Figure S2. uRRL was incubated with or without Ψ-Luc mRNAs at 30°C for 15 or 30 min. Buffer A was then added to stop the reactions. *In vitro* translation products were further treated with RNase A or left untreated. Western blot analysis of luciferase polypeptides was as described in Materials and methods. The position of the major prematurely terminated polypeptide (p48) is indicated. Asterisk indicates a nonspecific band that migrates slightly slower than p48 and is present in all the lanes including the minus mRNA control lanes.

```

AUGGAAGACGCCAAAAACAUAAGAAAGGCCCGCGCCAUUCUAUCCUCUAGAGGAUGGA 60
ACCGCUGGAGAGCAACUGCAUAAGGCUAUGAAGAGAUACGCCUGGUUCCUGGAACAAUU 120
GCUUUUACAGAUGCACAUUACGAGGUGAACAUACGUAACGCGGAAUACUUCGAAAUGUCC 180
GUUCGGUUGGCAGAAGCUAUGAAACGAUAUGGGCUGAAUACAAUACAGAAUCGUCGUG 240
UGCAGUGAAAAACUCUCUCAAUUCUUUAUGCCGGUGUUGGGCGCGUUAUUUAUCGGAGUU 300
GCAGUUGCGCCCGCGAACGACAUUUAUAAUGAACGUGAAUUGCUCUACAGUAUGAACAUU 360
UCGCAGCCUACCGUAGUGUUUGUUUCCAAAAAGGGGUUGCAAAAAUUUUGAACGUGCAA 420
AAAAAAUUACCAAUAAUCCAGAAAAUUUAUUAUCAUGGAUUCUAAAACGGAUUACCAGGGA 480
UUUCAGUCGAUGUACACGUAUCGUCACAUCUCAUCUACCUCGCCGUUUUAAUGAAUACGAU 540
UUUGUACCAGAGUCCUUUGAUCGUGACAAAACAAUUGCACUGAUAAUGAAUUCUCUGGA 600
UCUACUGGGUACCUAAAGGGUGUGGCCCUUCCGCAUAGAACUGCCUGCGUCAGAUUUCUG 660
CAUGCCAGAGAUCCUAUUUUUGGCAAUCAAUCCGGAUACUGCGAUUUUAAAGUGUU 720
GUUCCAUUCCAUCACGGUUUUGGAAUGUUUACUACACUCGGAUUUUGAUUUGUGGAUUU 780
CGAGUCGUCUUAAUGUAUAGAUUUGAAGAAGAGCUGUUUUUACGAUCCCUUACAGGAUUAC 840
AAAAUUCAAAGUUGCGUUGCUAGUACCAACCCUAUUUUUCAUUCUUCGCCAAAAGCACUCUG 900
AUUGACAAAUACGAUUUAUCUAAUUUACACGAAAUUGCUUUCUGGGGGCGCACCUCUUUCG 960
AAAGAAGUCGGGGAAGCGGUUGCAAAACGCUUCCAUCUCCAGGGAUACGACAAGGAUUAU 1020
GGGCUCACUGAGACUACAUCAGCUAUUCUGAUUACACCCGAGGGGGAUGAUAAACCGGGC 1080
GCGGUCGGUAAAAGUUGUCCAUUUUUUGAAGCGAAGGUUGUGGAUCUGGAUACCGGGAU 1140
ACGCUGGGCGUUAAUACAGAGAGGCGAAUUAUGUGUCAGAGGACCUAUGAUUAUGUCCGGU 1200
UAUGUAAACGAUCCGGAAGCGACCAACGCCUUGAUUGACAAGGAUGGAUGGCUACAUCU 1260
GGAGACAUAGCUUACUGGGACGAAGACGAACACUUCUUCAUAGUUGACCGCUUGAAGUCU 1320
UUAAUUAAAUACAAAGGAUGUCAGGUGGCCCCCGCUGAAUUGGAAUCGAUUAUGUUACAA 1380
CACCCCAACAUUCGACGCGGGCGUGGCAGGUCUUCCCGCGAUGACGCCGGUGAACUU 1440
CCCGCCGCCGUUGUUGUUUUGGAGCACGGAAGACGAUGACGGAAAAAGAGAUUCGUGGAU 1500
UACGUCGCCAGUCAAGUAACAACCGCGAAAAAGUUGCGCGGAGGAGUUGUUGUUGGAC 1560
GAAGUACCGAAAGGUCUUAACCGGAAAACUCGACGCAAGAAAAAUCAGAGAGAUCCUCAUA 1620
AAGGCCAAGAAGGGCGGAAAGUCCAAAUGUAA 1653

```

Figure S3. The coding sequence of Luc mRNA. The site of elongation arrest at the Ψ -modified U-rich sequence (nucleotides 1294-1326) is in italic. The sequence of nucleotides 1294-1317, which partially inhibits elongation, is underlined. The Ψ -modified U₁₃₂₂AA codon, which is the potential termination codon in the case of +1 frameshifting, is in bold italic.




Figure S4. Enhancement of translation by Ψ -nucleoside modifications in Luc mRNA in MN-untreated Krebs extract. The extracts were incubated with Luc or Ψ -Luc mRNA (4 μ g/ml) at 30°C for 1 h. One μ l aliquots of the reaction mixtures were assayed for luciferase activity. The mean values of the triplicate data \pm SD are shown.




Figure S5. Protease protection assay. uRRL was supplemented with CMMs and incubated with or without unmodified Luc or Ψ -Luc mRNAs at 30°C for 60 min. The reaction products were then treated with proteinase K in the absence or presence of 1% Triton X-100 or left untreated. Western blot analysis of luciferase polypeptides was as described in Materials and methods.